Our top pick for
ORIX Corporation is a credit services business based in the US. ORIX Corporation shares (IX) are listed on the NYSE and all prices are listed in US Dollars. ORIX Corporation employs 33,153 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$95.13|
|52-week range||$56.93 - $100.27|
|50-day moving average||$96.64|
|200-day moving average||$89.52|
|Wall St. target price||$105.38|
|Dividend yield||$78 (82.35%)|
|Earnings per share (TTM)||$7.41|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-1.63%|
|1 month (2021-09-24)||-0.99%|
|3 months (2021-07-26)||9.18%|
|6 months (2021-04-26)||16.82%|
|1 year (2020-10-26)||52.13%|
|2 years (2019-10-25)||23.83%|
|3 years (2018-10-26)||23.80%|
|5 years (2016-10-26)||26.79%|
Valuing ORIX Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ORIX Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ORIX Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, ORIX Corporation shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
ORIX Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $714.9 billion.
The EBITDA is a measure of a ORIX Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2,363.9 billion|
|Operating margin TTM||16.68%|
|Gross profit TTM||$837.1 billion|
|Return on assets TTM||1.85%|
|Return on equity TTM||7.08%|
|Market capitalisation||$22.8 billion|
TTM: trailing 12 months
There are currently 74,800 ORIX Corporation shares held short by investors – that's known as ORIX Corporation's "short interest". This figure is 23.6% down from 97,962 last month.
There are a few different ways that this level of interest in shorting ORIX Corporation shares can be evaluated.
ORIX Corporation's "short interest ratio" (SIR) is the quantity of ORIX Corporation shares currently shorted divided by the average quantity of ORIX Corporation shares traded daily (recently around 19632.545931759). ORIX Corporation's SIR currently stands at 3.81. In other words for every 100,000 ORIX Corporation shares traded daily on the market, roughly 3810 shares are currently held short.
However ORIX Corporation's short interest can also be evaluated against the total number of ORIX Corporation shares, or, against the total number of tradable ORIX Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ORIX Corporation's short interest could be expressed as 0% of the outstanding shares (for every 100,000 ORIX Corporation shares in existence, roughly 0 shares are currently held short) or 0.0003% of the tradable shares (for every 100,000 tradable ORIX Corporation shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ORIX Corporation.
Find out more about how you can short ORIX Corporation stock.
Dividend payout ratio: 53.31% of net profits
Recently ORIX Corporation has paid out, on average, around 53.31% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.14% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ORIX Corporation shareholders could enjoy a 4.14% return on their shares, in the form of dividend payments. In ORIX Corporation's case, that would currently equate to about $78 per share.
ORIX Corporation's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
ORIX Corporation's most recent dividend payout was on 10 December 2017. The latest dividend was paid out to all shareholders who bought their shares by 28 March 2021 (the "ex-dividend date").
ORIX Corporation's shares were split on a 6:5 basis on 5 June 2000. So if you had owned 5 shares the day before before the split, the next day you'd have owned 6 shares. This wouldn't directly have changed the overall worth of your ORIX Corporation shares – just the quantity. However, indirectly, the new 16.7% lower share price could have impacted the market appetite for ORIX Corporation shares which in turn could have impacted ORIX Corporation's share price.
Over the last 12 months, ORIX Corporation's shares have ranged in value from as little as $56.9301 up to $100.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ORIX Corporation's is 1.0906. This would suggest that ORIX Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ORIX Corporation provides diversified financial services in Japan, the Americas, Asia, Europe, Australasia, the Middle East, and internationally. The company's Corporate Financial Services and Maintenance Leasing segment is involved in the finance and fee; leasing and rental of automobiles, electronic measuring instruments, and IT-related equipment businesses; and provision of life insurance and environment and energy-related products and services. Its Real Estate segment develops, rents, and manages real estate properties; operates facilities; manages residential and office building; construction contracting; real estate brokerage; and REIT and real estate investment advisory services. The company's PE Investment and Concession segment engages in the private equity (PE) investment and concession businesses. Its Environment and Energy segment provides renewable energy; retails electric power; sells solar panels and electricity storage systems; and recycling and waste management services, as well as offers ESCO services. The company's Insurance segment sells life insurance products through agents, banks, and other financial institutions, as well as face-to-face and online. Its Banking and Credit segment provides banking and consumer finance services.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.